
➤ Blood investigations — unremarkable, except for mild elevated GGT/ALP.

➤ Ultrasound abdomen – mild dilated common bile duct. No choledocholithiasis. Distal bile duct not visible.



• CT Abdomen – mild dilated bile duct. No stones noted.





EUS versus MRCP

SN	EUS	MRCP				
	93.7 SD 7.1 (86.6; 100)	83.5 SD 18.6 (64.9; 100)				
SP	88,5 SD 16.1 (72.4; 100)	91.5 SD 10.7 (80.8; 100)				
PP	38.7 SD 21.8 (16.9; 60.5)					
PPV	89 SD 6.9 (82.1; 95.9)	87,8 SD 14.4 (73.4; 100)				
NPV	96.9 SD 2.6 (94.3; 99.5)	87,8 SD 15.5 (72.3; 100)				
Accuracy	93.3 SD 1.7 (91,6; 95)	89.7 SD 5.0 (84,7; 94.7)				

SN: Sensitivity, SD: Standard deviation, SP: Specificity, PP: Pretest probability,

PPV: Positive predictive value, NPV: Negative predictive value

• Endosc Ultrasound. 2016 Mar-Apr; 5(2): 118–128.

Endoscopic ultrasound versus magnetic resonance cholangiopancreatography in suspected choledocholithiasis: A systematic review

Case 2

65 year old male


- On and off recurrent abdominal pain.
- Diarrhea with weight loss.
- Chronic alcohol intake (significant).



- Stool Specs negative.
- CT abdomen normal
- Stool steatocrit elevated .
- Faecal eelastase low.

• Impression : chronic pancreatitis.

• ? Next step



• Early changes detected by EUS correlate with histologic changes of CP.

 EUS microcalcifications/lobularity/hyperechoic strands and foci.

Rosemont's criteria

Major criteria A	 1) Hyperechoic foci with shadowing (echogenic structure ≥2 mm length and width that shadow) 2) Lobularity with honeycombing (well circumscribed, ≥5 mm structures with enchaining rim and relatively echo pure center, contiguous ≥3 lobules) 3) Main pancreatic duct calculi (echogenic structure(s) within main pancreatic duct with shadowing)
Major criterion B	Honeycomb pattern of lobularity
Minor criteria	 Lobularity without honeycombing (noncontiguous lobules) Hyperechoic foci without shadowing Cysts Strands Irregular pancreatic duct contour Dilated side branches Main pancreatic duct dilatation Hyperechoic duct wall

EUS diagnosis of CP on the basis of Rosemont criteria.


- I. Consistent with CP
 - A. 1 Major A feature $+ \ge 3$ minor features
 - B. 1 Major A feature + major B feature
 - C. 2 Major A features
- II. Suggestive of CP
 - A. 1 Major A feature + < 3 minor features
 - B. 1 Major B feature $+ \ge 3$ minor features
 - C. \geq 5 Minor features (any)
- III. Indeterminate for CP
 - A. 3 to 4 Minor features, no major features
 - B. Major B feature alone or with <3 minor features
- IV. Normal
 - ≤2 Minor features, no major features

Case 3

• 58 year old

• Incidentally detected to have a pancreatic cyst on imaging (size 3 cm) at the pancreatic head with dilated pancreatic duct.

• Dudoenoscopy showed this



	Serous cystic tumor	Mucinous neoplasm	Main-duct intraductal papillary mucinous neoplasm	Branch-duct intraductal papillary mucinous neoplasm	Solid pseudopapillary neoplasm
Age of presentation	Variable, usually 5th to 7th decade	Variable, usually 5th to 7th decade	Variable, usually 5th to 7th decade	Variable, usually 5th to 7th decade	Usually 2nd to 3rd decade
Gender distribution	Females >males	Almost exclusively females	Females = males	Females = males	Females >males
Typical clinical presentation	Incidental or abdominal pain or mass effect	Incidental or abdominal pain or malignancy related	Incidental or pancreatitis or pancreatic insufficiency or malignancy related	Incidental or pancreatitis or malignancy related	Incidental or abdominal pain or mass effect
Typical imaging characteristics	Microcystic/honeycomb appearance Oligocystic appearance less common	Unilocular or septated cyst ± wall calcifications Solid component, if present, may suggest malignancy	Dilated main pancreatic duct ± parenchymal atrophy Solid component, if present, may suggest malignancy	Dilated pancreatic duct branch or branches Solid component, if present, may suggest malignancy	Solid and cystic mass ± calcifications
Typical aspirate	Thin, often bloody	Viscous	Viscous	Viscous or thin	Bloody
Typical carcinoembryonic antigen (CEA) level	<5 to 20 ng/mL in majority of lesions	>200 ng/mL in approximately 75% of lesions	>200 ng/mL in approximately 75% of lesions	>200 ng/mL in approximately 75% of lesions	Insufficient data
Typical glucose level	>50 mg/dL in majority	<50 mg/dL in majority	<50 mg/dL (limited data)	<50 mg/dL in majority	Insufficient data
Typical DNA analysis	Allelic loss affecting chromosome 3p and VHL mutation specific	K-ras mutation specific (>90%), not sensitive (<50%) TP53, PTEN, PIK3CA, high DNA amount or high-amplitude allelic loss seen in malignancy	K-ras and GNAS mutation specific (>90%), not sensitive (<50%) TP53, PTEN, PIK3CA, high DNA amount or high-amplitude allelic loss seen in malignancy	K-ras and GNAS mutation specific (>90%), not sensitive (<50%) TP53, PTEN, PIK3CA, high DNA amount or high-amplitude allelic loss seen in malignancy	CTNNB1 mutation specific
Relative malignant potential	Negligible	Moderate	High	Low to moderate	Moderate to high
Treatment	Resect if symptomatic	Resection	Resection and post-	Closely monitor or	Resection




Fig. 6?Diagnostic and therapeutic procedure for IPMNs in accordance with the revised Fukuoka Guidelines [3]